CR20140537A - Compuesto heterocíclico nitrogenado - Google Patents

Compuesto heterocíclico nitrogenado

Info

Publication number
CR20140537A
CR20140537A CR20140537A CR20140537A CR20140537A CR 20140537 A CR20140537 A CR 20140537A CR 20140537 A CR20140537 A CR 20140537A CR 20140537 A CR20140537 A CR 20140537A CR 20140537 A CR20140537 A CR 20140537A
Authority
CR
Costa Rica
Prior art keywords
heterocyclic compound
nitrogen heterocyclic
compound
pde2a
schizophrenia
Prior art date
Application number
CR20140537A
Other languages
English (en)
Inventor
Satoshi Mikami
Shinji Nakamura
Tomoko Ashizawa
Shigekazu Sasaki
Takahiko Taniguchi
Izumi Nomura
Masanori Kawasaki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR20140537A publication Critical patent/CR20140537A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se provee un compuesto que tiene una acción inhibidora selectiva de la PDE2A, y es útil como agente para la profilaxis o tratamiento de esquizofrenia, la enfermedad de Alzheimer y similar. Un compuesto representado por la fórmula (1): [en donde cada símbolo es como se describe en la descripción] o una sal del mismo
CR20140537A 2012-04-25 2014-11-24 Compuesto heterocíclico nitrogenado CR20140537A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012100374 2012-04-25
JP2012283470 2012-12-26
PCT/JP2013/062140 WO2013161913A1 (ja) 2012-04-25 2013-04-24 含窒素複素環化合物

Publications (1)

Publication Number Publication Date
CR20140537A true CR20140537A (es) 2015-02-03

Family

ID=49483221

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140537A CR20140537A (es) 2012-04-25 2014-11-24 Compuesto heterocíclico nitrogenado

Country Status (25)

Country Link
US (2) US9469637B2 (es)
EP (1) EP2848618B1 (es)
JP (1) JP6157455B2 (es)
KR (1) KR20150005936A (es)
AU (1) AU2013253516B2 (es)
BR (1) BR112014025711A8 (es)
CA (1) CA2869730A1 (es)
CL (1) CL2014002880A1 (es)
CO (1) CO7141410A2 (es)
CR (1) CR20140537A (es)
DO (1) DOP2014000243A (es)
EA (1) EA029892B1 (es)
GE (1) GEP20166554B (es)
HK (1) HK1203500A1 (es)
IL (1) IL235048B (es)
MX (1) MX361539B (es)
MY (1) MY173949A (es)
NZ (1) NZ631258A (es)
PE (1) PE20142258A1 (es)
PH (1) PH12014502396A1 (es)
SG (1) SG11201406552UA (es)
TN (1) TN2014000416A1 (es)
UA (1) UA115057C2 (es)
WO (1) WO2013161913A1 (es)
ZA (1) ZA201408644B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201406552UA (en) 2012-04-25 2014-11-27 Takeda Pharmaceutical Nitrogenated heterocyclic compound
JP6205356B2 (ja) 2012-07-13 2017-09-27 武田薬品工業株式会社 複素環化合物
JP6280912B2 (ja) 2013-03-14 2018-02-14 武田薬品工業株式会社 複素環化合物
EP3018126A4 (en) 2013-07-03 2016-12-07 Takeda Pharmaceuticals Co HETEROCYCLIC COMPOUND
US10472376B2 (en) 2013-07-03 2019-11-12 Takeda Pharmaceutical Company Limited Amide compound
JPWO2015012328A1 (ja) * 2013-07-24 2017-03-02 武田薬品工業株式会社 複素環化合物
JPWO2015060368A1 (ja) * 2013-10-23 2017-03-09 武田薬品工業株式会社 複素環化合物
WO2015096651A1 (en) 2013-12-23 2015-07-02 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as pde2 inhibitors
JP2017114764A (ja) * 2014-04-25 2017-06-29 武田薬品工業株式会社 片頭痛治療剤
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
WO2016154081A1 (en) 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as pde2 inhibitors
US10195201B2 (en) 2015-05-05 2019-02-05 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as PDE2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
US10647727B2 (en) 2015-06-25 2020-05-12 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
US11419874B2 (en) 2017-11-23 2022-08-23 Oslo University Hospital Hf Treatment of tachycardia
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CN113214172A (zh) * 2021-04-25 2021-08-06 西南大学 氟康唑中间体还原胺化产物的制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001938A1 (en) 1990-07-20 1992-02-06 City Of Hope Derivatization of c-terminal proline
DE4211239C2 (de) 1992-04-03 1995-11-16 Max Planck Gesellschaft Arzneimittel gegen Herz-Kreislauf-Erkrankungen
JPH06145169A (ja) 1992-09-17 1994-05-24 Nippon Soda Co Ltd 新規な含窒素５員環化合物、その製造方法及び有害生物防除剤
JP3601898B2 (ja) 1996-02-14 2004-12-15 俊隆 鍋島 薬物依存形成抑制剤
JPH11292877A (ja) 1998-04-09 1999-10-26 Yamanouchi Pharmaceut Co Ltd １，４−ジ置換ピリドピラジン誘導体
JP2003526608A (ja) 1998-10-15 2003-09-09 バイオイメージ エイ／エス 再分布及び／又は標的化での干渉によって得られる特異的治療の介入
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US7655423B2 (en) 1999-06-14 2010-02-02 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
US7135498B1 (en) 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
DE60040299D1 (de) 1999-06-14 2008-10-30 Ford Henry Health System Stickstoffmonoxid-donoren zum induzieren von neurogenese
FR2796947A1 (fr) 1999-07-30 2001-02-02 Aventis Pharma Sa Nouveaux derives 8-carbonyl chromanes, leur preparation et leur utilisation en therapeutique
EP1218003A4 (en) 1999-09-13 2004-02-11 David M Swope COMPOSITION AND METHOD FOR REDUCING NEUROLOGICAL SYMPTOMATOLOGY
WO2002009713A2 (de) 2000-08-01 2002-02-07 Bayer Aktiengesellschaft Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung
US20020119978A1 (en) 2000-12-05 2002-08-29 Swope David M. Composition and method for decreasing neurologic symptomatology
DE10064105A1 (de) 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
JP4535680B2 (ja) 2001-04-16 2010-09-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規１ｈ−インダゾール化合物
IL162850A0 (en) 2002-01-04 2005-11-20 Ford Henry Health System Nitric oxide donors for treatment of disease and injury
DE10224462A1 (de) 2002-06-03 2003-12-11 Bayer Ag Verwendung von cGMP stimulierenden Verbindungen
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
NZ540167A (en) 2002-10-30 2007-06-29 Neuro3D Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses
EP1597386A1 (en) 2002-11-13 2005-11-23 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a)
WO2004060872A1 (en) 2002-12-30 2004-07-22 Eli Lilly And Company Factor xa inhibitors
JP2006519243A (ja) 2003-03-04 2006-08-24 アルタナ　ファルマ　アクチエンゲゼルシャフト プリン−６−オン誘導体
GB2404658A (en) 2003-08-07 2005-02-09 Bayer Ag Quinoxalinone derivatives and their use in the treatment of diseases
WO2005035534A1 (ja) 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
JP2005145840A (ja) 2003-11-12 2005-06-09 Nippon Soda Co Ltd 縮合ヘテロ環誘導体及び農園芸用殺菌剤
US20070135457A1 (en) 2003-12-16 2007-06-14 Pfizer Inc. Pyrido[2,3-d]pyrimidine-2,4-diamines as pde2 inhibitors
CA2557004A1 (en) 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
AU2005267884B2 (en) 2004-07-29 2011-04-21 Merck Sharp & Dohme Corp. Potassium channel inhibitors
MX2007008137A (es) 2005-01-05 2007-07-19 Altana Pharma Ag Triazoloftalazinas como inhibidores de pde2.
WO2006072612A2 (en) 2005-01-05 2006-07-13 Nycomed Gmbh Triazolophthalazines as pde2- inhibitors
WO2007094755A2 (en) 2005-02-04 2007-08-23 Massachusetts Institute Of Technology Compositions and methods for modulating cognitive function
WO2007020521A1 (en) 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Pyridoyrazinones as pde-5 inhibitors
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
TW200815436A (en) 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
WO2007146230A2 (en) 2006-06-14 2007-12-21 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
DE102006048693A1 (de) * 2006-10-14 2008-04-17 Bayer Healthcare Ag Inhibition der PDE2A
US20090325936A1 (en) 2006-12-20 2009-12-31 Bilodeau Mark T Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
AU2008289037B2 (en) 2007-08-22 2012-03-01 Novartis Ag 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
JP5375824B2 (ja) 2008-05-14 2013-12-25 アステラス製薬株式会社 アミド化合物
US20100120763A1 (en) 2008-11-07 2010-05-13 Wyeth Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases
WO2010054253A1 (en) * 2008-11-07 2010-05-14 Biotie Therapies Gmbh Triazine derivatives as inhibitors of phosphodiesterases
EP2401275B1 (en) 2009-02-24 2013-07-24 Respiratorius AB Naphthyridine derivatives having bronchodilating activity
US8691827B2 (en) 2009-08-17 2014-04-08 Merck Sharp & Dohme Corp. Amino tetrahydro-pyridopyrimidine PDE10 inhibitors
KR102097664B1 (ko) 2009-10-06 2020-04-06 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｐｄｋ１ 저해제로서 유용한 헤테로시클릭 화합물
MX2012004995A (es) * 2009-10-29 2012-10-03 Sirtris Pharmaceuticals Inc Piridinas biciclicas y analogos como moduladores de sirtuina.
WO2012018909A1 (en) 2010-08-04 2012-02-09 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US20130184462A1 (en) 2010-09-30 2013-07-18 Council Of Scientific & Industrial Research Method for predicting and modeling anti-psychotic activity using virtual screening model
EP2627178B1 (en) 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
US9265735B2 (en) 2010-11-30 2016-02-23 New York University Methods for screening to identify therapeutic agents for Alzheimer's disease and use thereof
CN103702985B (zh) 2010-12-23 2016-02-17 默沙东公司 作为crth2受体调节剂的喹喔啉和氮杂喹喔啉
CA2836202A1 (en) 2011-05-30 2012-12-06 Astellas Pharma Inc. Imidazopyridine compounds
US9096602B2 (en) 2011-06-22 2015-08-04 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors
CN103946220B (zh) 2011-11-03 2017-12-22 施万生物制药研发Ip有限责任公司 含有片段{2‑[4‑(联苯‑4‑基)‑1h‑咪唑‑2‑基]吡咯烷‑1‑羰基甲基}胺的杆状丙型肝炎病毒抑制剂
SG11201406552UA (en) 2012-04-25 2014-11-27 Takeda Pharmaceutical Nitrogenated heterocyclic compound
JP6205356B2 (ja) 2012-07-13 2017-09-27 武田薬品工業株式会社 複素環化合物
JPWO2015012328A1 (ja) 2013-07-24 2017-03-02 武田薬品工業株式会社 複素環化合物

Also Published As

Publication number Publication date
JPWO2013161913A1 (ja) 2015-12-24
MY173949A (en) 2020-02-28
US10017508B2 (en) 2018-07-10
CA2869730A1 (en) 2013-10-31
HK1203500A1 (en) 2015-10-30
ZA201408644B (en) 2016-02-24
BR112014025711A8 (pt) 2018-01-16
PH12014502396B1 (en) 2014-12-22
DOP2014000243A (es) 2014-12-31
EP2848618A1 (en) 2015-03-18
NZ631258A (en) 2016-11-25
UA115057C2 (uk) 2017-09-11
PE20142258A1 (es) 2015-01-15
EA029892B1 (ru) 2018-05-31
PH12014502396A1 (en) 2014-12-22
MX2014013011A (es) 2015-01-12
EA201491936A1 (ru) 2015-03-31
US20170129887A1 (en) 2017-05-11
KR20150005936A (ko) 2015-01-15
US9469637B2 (en) 2016-10-18
US20150105373A1 (en) 2015-04-16
SG11201406552UA (en) 2014-11-27
CO7141410A2 (es) 2014-12-12
CN104245698A (zh) 2014-12-24
TN2014000416A1 (en) 2016-03-30
BR112014025711A2 (pt) 2017-07-04
AU2013253516A2 (en) 2015-04-02
GEP20166554B (en) 2016-10-10
AU2013253516B2 (en) 2017-10-12
EP2848618A4 (en) 2015-11-11
EP2848618B1 (en) 2018-03-14
WO2013161913A1 (ja) 2013-10-31
MX361539B (es) 2018-12-10
IL235048B (en) 2018-11-29
CL2014002880A1 (es) 2015-02-06
JP6157455B2 (ja) 2017-07-05
AU2013253516A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
CR20140537A (es) Compuesto heterocíclico nitrogenado
CO6592104A2 (es) Compuesto heterociclico
EA201591612A1 (ru) ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ
BR112015029686A2 (pt) composições para o tratamento de superfícies compreendendo corantes fotocrômicos
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
CY1122805T1 (el) Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
CO2017003699A2 (es) Compuesto heterocíclico
CL2014003123A1 (es) 5-amino [1,4], tiazinas como inhibidores de bace1; uso del compuesto contra la enfermedad de alzheimer.
ECSP14011792A (es) Inhibidores de iap
AR128158A2 (es) Compuesto heterocíclico
BR112015016033A8 (pt) composições farmacêuticas para tratamento de infecções por bactérias, e seus usos
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
CL2016000884A1 (es) Derivados de piperazina y su uso como medicamento.
PH12015500399A1 (en) Azaindolines
UY35650A (es) Compuesto heterocíclico
MX2015012043A (es) Agonistas muscarinicos.
UY35165A (es) Método profiláctico o terapéutico para el síndrome de sjogren
BR112014026158A2 (pt) métodos e composições para o tratamento de infecções virais
ECSP12011747A (es) Derivado de anillo heterocíclico fusionado y uso del mismo
ECSP14026022A (es) Compuesto heterocíclico nitrogenado
UY35095A (es) Compuestos heterocíclicos que contienen nitrógeno
AR084421A1 (es) Betametasona como agente antibacteriano
EA201700037A1 (ru) Производные 2н-хромена в качестве анальгезирующих средств
PL405509A1 (pl) Środek do ochrony roślin